Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ILLR vs IVF: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IVF Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 4–4 Matrix Metrics)

IVF Overall Winner 6-Pillar Tally: ILLR 0 – 4 IVF (2 Tie) Matrix Metrics: ILLR 4 – 4 IVF

As of Nov 16, 2026, INVO Fertility, Inc. (IVF) is the stronger overall head-to-head candidate over Triller Group Inc. (ILLR) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ILLR carries a Unified Composite Score of 48.6/100 (HOLD) at $0.18 (N/M Forward P/E, -432.7% operating margin), whereas IVF carries 29.8/100 (SELL) at $2.38 (N/M Forward P/E, -78.7% operating margin).

  • Composite vs. Pillar Nuance: While ILLR currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. IVF 29.8/100 SELL), IVF captures the overall institutional head-to-head verdict (4–4 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-78.7% vs. -432.7% operating margin) and revenue trajectory (+16.7% vs. -5.2% YoY).
  • Technical & Structure Timing Caution: ILLR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.8); meanwhile IVF trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 76.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ILLR vs IVF
ILLR NASDAQ
Triller Group Inc. Common Stock
Investment Advice
$0.18
-23.04% 1D
Market Cap $4.7M
TTM Revenue $22M
Forward P/E N/M
Beta / 30D Vol -10.16β · 177% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 45.0 Fund 49.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -44.3%), weak momentum, RSI 18
RSI-14: 17.8 · SMA20: $0.46 · SMA50: $0.80
IVF NASDAQ Head-to-Head Winner
INVO Fertility, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$2.38
-8.46% 1D
Market Cap $3.2M
TTM Revenue $7.5M
Forward P/E N/M
Beta / 30D Vol -7.15β · 888% Vol
Unified Composite Score
29.8 / 100 SELL
Tech 50.0 Fund 26.0 Flow 50.0 Mom 34.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (21.7% over 20 days), RSI 76
RSI-14: 76.0 · SMA20: $1.59 · SMA50: $1.14

6-Pillar Scorecard Institutional Category Breakdown (ILLR 0 – 4 IVF)

Columns: Metric · ILLR · IVF
1. Valuation Multiples IVF
Forward P/E N/M N/M
Trailing P/E N/M 0.0x
PEG Ratio N/M N/M
EV / Revenue 0.2x 0.3x
2. Growth & Scale IVF
Revenue Growth (YoY) -5.2% +16.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $22M $7.5M
Market Cap $4.7M $3.2M
3. Profitability & Quality IVF
Gross Margin N/A 35.3%
Operating Margin -432.7% -78.7%
Net Profit Margin 0.0% -92.3%
Return on Equity (ROE) 0.0% -72.7%
4. Balance Sheet & Cash Flow IVF
Cash Generation (TTM) -$144M EBITDA -$5.4M
Cash Flow Margin N/A -71.9%
Net Cash / Leverage 0.0% ROE -$919,426 Net Debt (0.27x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Software - Application Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ILLR (4) vs IVF (4)
Institutional Metric ILLR IVF Criterion Row Edge
Market Capitalization
Scale
$4.7M $3.2M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M 0.0x Lower Multiple IVF
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-5.2% +16.7% Higher Growth IVF
Operating Margin (TTM)
Profitability
-432.7% -78.7% Higher Margin IVF
Net Profit Margin
Profitability
0.0% -92.3% Higher Margin ILLR
Return on Equity (ROE)
Capital Efficiency
0.0% -72.7% Higher ROE ILLR
52-Week Range Position
Momentum
1% ($0–$5) 49% ($0–$5) Stronger Trend IVF
Beta / 30D Volatility
Risk Regime
-10.16β · 177% Vol -7.15β · 888% Vol Lower Realized Risk ILLR
Unified Institutional Score
Composite Signal
48.6 / 100 (HOLD) 29.8 / 100 (SELL) Higher Composite ILLR
Trailing 12M Revenue (USD)
Operating Scale
$22M $7.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 35.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.2x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$144M EBITDA (0.0% ROE) -$5.4M (-$919,426 Net Debt (0.27x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IVF +61.21 pp
ILLR: -80.49% · IVF: -19.28%
3M Horizon IVF +54.78 pp
ILLR: -92.66% · IVF: -37.88%
6M Horizon IVF +47.45 pp
ILLR: -71.73% · IVF: -24.28%
1Y Horizon IVF +125.04 pp
ILLR: -65.7% · IVF: +59.34%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ILLR Revenue IVF Revenue ILLR Op. Margin IVF Op. Margin Margin Leader
FY2018 N/A $0M N/A -532.8% IVF
FY2019 N/A $0M N/A -120.8% IVF
FY2020 N/A $0M N/A -531.7% IVF
FY2021 $10M $0M -73.7% -125.4% ILLR
FY2022 $30M $0M -91.2% -1292.5% ILLR
FY2023 $50M $0M -79.5% -224.0% ILLR
FY2024 $30M $10M -411.9% -101.0% IVF
FY2025 $20M $10M -640.1% -105.8% IVF

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ILLR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ILLR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IVF UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IVF Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ILLR Moat Profile Cyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $4.7M market capitalization and -432.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IVF Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $3.2M market capitalization and -78.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ILLR vs IVF Key Questions & Quantitative Answers

As of Nov 16, 2026, INVO Fertility, Inc. (IVF) is the stronger overall head-to-head candidate over Triller Group Inc. (ILLR) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ILLR carries a Unified Composite Score of 48.6/100 (HOLD) at $0.18 (N/M Forward P/E, -432.7% operating margin), whereas IVF carries 29.8/100 (SELL) at $2.38 (N/M Forward P/E, -78.7% operating margin). Composite vs. Pillar Nuance: While ILLR currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. IVF 29.8/100 SELL), IVF captures the overall institutional head-to-head verdict (4–4 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-78.7% vs. -432.7% operating margin) and revenue trajectory (+16.7% vs. -5.2% YoY). Technical & Structure Timing Caution: ILLR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.8); meanwhile IVF trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 76.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IVF leads the Growth & Scale pillar: ILLR posts -5.2% YoY revenue growth and +0.0% YoY earnings growth on $22M TTM revenue (N/A gross margin, -432.7% operating margin), compared with IVF at +16.7% YoY revenue growth and +0.0% YoY earnings growth on $7.5M TTM revenue (35.3% gross margin, -78.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ILLR cumulative revenue shifted +100.0% while IVF shifted +0.0%. In operating R&D and SG&A reinvestment, ILLR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IVF.

IVF screens cheaper on headline valuation multiples. ILLR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.2x EV/Revenue (unreported EBITDA margin), whereas IVF trades at N/M Forward P/E, 0.0x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-71.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ILLR (0.0% ROE) versus IVF (-72.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ILLR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-10.16β · 177% Vol realized risk). By comparison, IVF carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.15β · 888% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.